Pages that link to "Q34995211"
Jump to navigation
Jump to search
The following pages link to Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study (Q34995211):
Displaying 50 items.
- Renal cell carcinoma: Evolving and emerging subtypes (Q24629153) (← links)
- Platinum-induced hearing loss after treatment for childhood cancer (Q26470526) (← links)
- Overview and recent advances in the treatment of neuroblastoma (Q30238693) (← links)
- Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens (Q30987402) (← links)
- Second malignancies in patients with neuroblastoma: the effects of risk-based therapy (Q34543549) (← links)
- Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma (Q34660375) (← links)
- Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma (Q34703990) (← links)
- G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic (Q34981973) (← links)
- The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. (Q34982031) (← links)
- Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells (Q34997000) (← links)
- Impairments that influence physical function among survivors of childhood cancer (Q35082766) (← links)
- A systematic review of selected musculoskeletal late effects in survivors of childhood cancer (Q35108050) (← links)
- Might salicylate exert benefits against childhood cancer? (Q35602134) (← links)
- Physical and mental health status and health behaviors of childhood cancer survivors: Findings from the 2009 BRFSS survey (Q35904706) (← links)
- Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission (Q36212437) (← links)
- The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. (Q36411061) (← links)
- The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma (Q36692848) (← links)
- Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk (Q36736612) (← links)
- Potentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese children. (Q37117136) (← links)
- Osteochondroma in long-term survivors of high-risk neuroblastoma (Q37145905) (← links)
- LMO1 gene polymorphisms contribute to decreased neuroblastoma susceptibility in a Southern Chinese population (Q37225669) (← links)
- Common variations within HACE1 gene and neuroblastoma susceptibility in a Southern Chinese population. (Q37641476) (← links)
- Immunocombination therapy for high-risk neuroblastoma (Q37991024) (← links)
- Neuroblastoma: a review of management and outcome (Q38005038) (← links)
- Ten challenges in the management of neuroblastoma. (Q38029366) (← links)
- Emerging drugs for neuroblastoma (Q38108399) (← links)
- At the frontier of progress for paediatric oncology: the neuroblastoma paradigm (Q38161274) (← links)
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity (Q38734933) (← links)
- Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. (Q38940398) (← links)
- Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. (Q39052883) (← links)
- Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review (Q39114900) (← links)
- Life partnerships in childhood cancer survivors, their siblings, and the general population (Q39330482) (← links)
- Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation (Q39391640) (← links)
- Checkpoint kinase inhibitor synergizes with DNA‐damaging agents in G1 checkpoint‐defective neuroblastoma (Q39620511) (← links)
- Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line (Q39701739) (← links)
- Health-Related Quality of Life in Survivors of High-Risk Neuroblastoma After Stem Cell Transplant: A National Population-Based Perspective. (Q39749852) (← links)
- Survival and late effects in children with stage 4 neuroblastoma (Q39971015) (← links)
- Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma. (Q40129277) (← links)
- Engagement and experience with cancer-related follow-up care among young adult survivors of childhood cancer after transfer to adult care (Q41456144) (← links)
- Reassessing dose constraints of organs at risk in children with abdominal neuroblastoma treated with definitive radiation therapy: a correlation with late toxicity (Q41643569) (← links)
- The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma. (Q42095135) (← links)
- LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study (Q42371564) (← links)
- Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. (Q42697385) (← links)
- Physical and psychological outcome in long-term survivors of childhood malignant solid tumor in Japan (Q45852527) (← links)
- Achievement of developmental milestones in emerging and young adults with and without pediatric chronic illness--a meta-analysis (Q47780006) (← links)
- Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (Q48234866) (← links)
- Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience (Q50357815) (← links)
- Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC. (Q51173478) (← links)
- Genetic susceptibility to neuroblastoma: current knowledge and future directions. (Q52339753) (← links)
- Methods to Assess Adverse Health-Related Outcomes in Cancer Survivors (Q53089779) (← links)